The Frederick National Lab is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc. The lab addresses some of the most urgent and intractable problems in the biomedical sciences in cancer and AIDS, drug development and first-in-human clinical trials, applications of nanotechnology in medicine, and rapid response to emerging threats of infectious disease.
Our scientists conduct basic, hypothesis-driven research and collaborative studies that span a wide range, including genetics, genomics, protein science, proteomics, bioinformatics, high-performance biomedical computing, laboratory animal sciences, and clinical operations.
Our Nanotechnology Characterization Laboratory, a partnership with the U.S. Food and Drug Administration and the National Institutes of Standards and Technology, is pioneering medical applications of nanotechnology to fight cancer, AIDS, and other diseases.
We operate two Current Good Manufacturing Practice (GMP) facilities that produce pharmaceuticals for first-in-human clinical trials. One facility supports drug discovery and development for the National Cancer Institute and the other for the National Institute of Allergy and Infectious Diseases.
We anchor the national RAS Initiative, an intensive project to understand the mechanism of a mutant protein implicated in one-third of cancers and almost all pancreatic cancers, and how to create therapeutic agents that will be effective against all these cancers. The Frederick National Lab serves as the hub-and-spoke model that reaches out to academic, commercial, government, and nonprofit organizations across the country in a united effort.
As a shared national resource, we offer access to a suite of advanced biomedical technologies, provide selected science and technology services, and maintain vast repositories of research materials available to biomedical investigators nationwide. These research materials include more than 15 million biological specimens, frozen tumor samples, research reagents, and genetically engineered mouse models of human cancers.
The Frederick National Lab provides rapid response to emerging health threats, mobilizing effective resources to address disease outbreaks and investigate newly recognized pathogens. We also monitor more than 400 ongoing human clinical trials in the United States and overseas.
The lab is accelerating progress in the fight against cancer, AIDS, and other infectious diseases; stimulating research collaborations; and creating opportunities for technology transfer and business and economic development. These activities represent the necessary investment to maximize the benefits of scientific discovery and innovation on human health.